已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES

医学 痛风 托弗斯 耐火材料(行星科学) 内科学 安慰剂 尿酸 临床试验 胃肠病学 黄嘌呤氧化酶 高尿酸血症 病理 酶 替代医学 化学 物理 天体生物学 生物化学
作者
Herbert S. B. Baraf,Alan Kivitz,S. Rhodes,Sheldon S. Leung,O. Folarin,Tania C González-Rivera,Joanna Sobierska,J. Christie,A. Patel,Wesley H. DeHaan,Rehan Azeem,Peter G. Traber
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82: 200-201 被引量:6
标识
DOI:10.1136/annrheumdis-2023-eular.7084
摘要

Background

Despite availability of effective therapies for gout, a small proportion of patients suffer from refractory gout and/or are intolerant to standard therapies [1]. In these patients, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL may lead to severe clinical manifestations for which uricase-based therapies can be highly effective, though also immunogenic. SEL-212 is a once-monthly, novel 2-component, sequential uricase-based infusion therapy being investigated in patients with refractory gout. SEL-212 consists of an infusion of tolerogenic nanoparticles containing rapamycin (SEL-110) followed by pegadricase (SEL-037). The intent of this drug combination is to inhibit the formation of anti-uricase antibodies without the need for separate immunosuppressant therapies [2].

Objectives

DISSOLVE I and II (D1 and D2, respectively) evaluated the safety and efficacy of SEL-212 in adults with refractory gout.

Methods

D1 (US Study, 12 months) and D2 (Global Study, 6 months), were placebo-controlled, double-blind, randomized clinical trials that evaluated two dose levels of SEL-110 (0.15 mg/kg [high-dose] or 0.1 mg/kg [low-dose]) prior to SEL-037 (0.2 mg/kg) infusion in adults (19-80 years). Participants with a history of symptomatic gout were enrolled if they had ≥ 3 gout flares within 18 months prior to screening or ≥ 1 tophus or a current diagnosis of gouty arthritis, failed to normalize sUA and control symptoms with any xanthine oxidase inhibitor, and were not previously exposed to a uricase-based therapy. Participants were randomized 1:1:1 between the two doses of SEL-212 and placebo administered intravenously every 28 days for 6 treatments. D1 participants were continued in a 6-month blinded extension phase under the initial treatment conditions (Fig. 1). The primary endpoint was defined as the percentage of participants who achieved and maintained sUA < 6 mg/dL for ≥ 80% of the sixth 28-day treatment period (TP6) in the active treatment groups versus placebo (response rate). Safety and tolerability were assessed through monitoring of adverse events (AEs) and laboratory testing.

Results

A total of 265 participants (D1, n=112 (96% male, 66% ≥ 50 years); D2, n=153 (97% male, 72% ≥ 50 years) were randomized into the three treatment arms. Response rates in all treatment groups were significantly different from placebo (p ≤ 0.0015), with 56% and 47% of participants responding in the high-dose group and 48% and 41% in the low-dose group for D1 and D2, respectively (Table 1). The response rates in participants aged ≥ 50 years were 65% and 48% in the high-dose groups and 47% and 45% in the low-dose groups for D1 and D2, respectively (p ≤ 0.0044 vs placebo). Across all participants in the treatment groups, median sUA levels were reduced by ~96% and ~75% from baseline at TP6 for D1 and D2, respectively (p<0.001 vs placebo). The safety profile of SEL-212 was favorable, with 3.4% and 4.5% of participants experiencing infusion reactions in the high and low-dose groups, respectively. Reports of gout flares were comparable between treatment groups and placebo. Six participants (3.4%) in the pooled active treatment groups experienced treatment-related serious AEs (n=4 anaphylaxis, n=2 gout flares).

Conclusion

In the DISSOLVE trials, once-monthly treatment with SEL-212 demonstrated statistically significant response rates and reductions in sUA versus placebo. The safety profile of SEL-212 was consistent with that of uricase therapies. Targeted immunomodulation with SEL-212 has the potential to provide a new uricase-based treatment option for patients with gout refractory to conventional therapies without the need for traditional immunosuppressants.

References

[1] Edwards NL. Arthritis Rheum 2008;58(9):2587-90. [2] Sands E, et al. Nat Commun 2022;13:272.

Acknowledgments

We would like to acknowledge all participants, investigators, and study personnel involved in the DISSOLVE phase III clinical studies. Writing support provided by Micheal Wilson, PhD, of Swedish Orphan Biovitrum.

Disclosure of Interests

Herbert S.B. Baraf Consultant of: Horizon Pharmaceuticals, Swedish Orphan Biovitrum, Selecta Biosciences, Speakers bureau: Horizon Pharmaceuticals, Grant/research support from: Horizon Pharmaceuticals, Swedish Orphan Biovitrum, Alan Kivitz Consultant of: AXDEV Group, Amgen, Pfizer, Janssen, Boehringer Ingelheim, AbbVie, Flexion, Gilead, Grünenthal, Orion, Regeneron, Sun Pharma Advance Research, and ECOR1, Speakers bureau: Merck & Co, Eli Lilly, Novartis, Pfizer, Flexion, AbbVie, Amgen, Genentech, Regeneron, UCB, Horizon, and GSK, Shareholder of: Pfizer, GSK, Gilead, Novartis, and Amgen, Sheri Rhodes Consultant of: Selecta Biosciences, Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences, Sheldon Leung Consultant of: Selecta Biosciences, Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences, Olu Folarin Consultant of: Selecta Biosciences, Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences, Tania Gonzalez-Rivera Consultant of: Swedish Orphan Biovitrum, Employee of: Swedish Orphan Biovitrum, Joanna Sobierska Employee of: Swedish Orphan Biovitrum, Jacquie Christie Shareholder of: GSK Pharma, Employee of: Swedish Orphan Biovitrum, Anand Patel Speakers bureau: Lexicon Pharmaceuticals, Wesley DeHaan Consultant of: Selecta Biosciences, Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences, Rehan Azeem Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences, Peter Traber Consultant of: Selecta Biosciences, Shareholder of: Selecta Biosciences, Employee of: Selecta Biosciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
激动的元瑶完成签到 ,获得积分10
2秒前
温某人发布了新的文献求助10
3秒前
4秒前
背后棒球发布了新的文献求助10
4秒前
共享精神的应助被标致枫叶采纳,获得10
4秒前
5秒前
慈祥的大船完成签到 ,获得积分10
7秒前
song完成签到 ,获得积分20
9秒前
王大壮完成签到,获得积分0
11秒前
shamo完成签到,获得积分20
11秒前
13秒前
科研通AI2S的应助被bji采纳,获得10
13秒前
树123发布了新的文献求助10
16秒前
粗心的代芙完成签到,获得积分10
18秒前
标致枫叶发布了新的文献求助10
20秒前
李健的小迷弟的应助被山有树采纳,获得10
21秒前
CipherSage的应助被妍妍采纳,获得10
21秒前
终须有完成签到 ,获得积分10
22秒前
T0Yu发布了新的文献求助10
23秒前
丘比特的应助被博修采纳,获得10
23秒前
深情安青的应助被yang采纳,获得10
25秒前
爆米花的应助被yang采纳,获得10
25秒前
大个的应助被yang采纳,获得10
25秒前
JamesPei的应助被yang采纳,获得10
25秒前
SciGPT的应助被yang采纳,获得10
25秒前
科研通AI2S的应助被yang采纳,获得10
25秒前
情怀的应助被yang采纳,获得10
26秒前
Orange的应助被yang采纳,获得10
26秒前
搜集达人的应助被yang采纳,获得10
26秒前
充电宝的应助被yang采纳,获得10
26秒前
29秒前
29秒前
彭于晏的应助被xxdwyd采纳,获得10
31秒前
我吃吃吃吃吃吃完成签到 ,获得积分10
31秒前
32秒前
32秒前
daomaihu发布了新的文献求助100
33秒前
mycoplasma完成签到 ,获得积分10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172605
求助须知:如何正确求助?哪些是违规求助? 9565323
关于积分的说明 21778953
捐赠科研通 7764352
什么是DOI,文献DOI怎么找? 3431411
关于科研通互助平台的介绍 2555301
邀请新用户注册赠送积分活动 2476394